Verdonck L F, Witteveen E O, van Heugten H G, Rozemuller E, Rijksen G
Department of Haematology, University Hospital Utrecht, The Netherlands.
Cancer Res. 1990 Jul 1;50(13):4020-5.
We studied the effects of the alkyl-lysophospholipid, 1-octadecyl-2-methyl-sn-glycerol-3-phosphocholine (ALP), on human leukemia cells from 56 patients with various leukemias and on normal bone marrow progenitors in order to assess the application of ALP as an in vitro marrow-purging agent. The tumoricidal activity was analyzed by the elimination of clonogenic leukemia cells (leukemic colony-forming cells), by the inhibition of the proliferative capacity [( 3H]thymidine incorporation) of leukemia cells, and by the elimination of viable leukemia cells measured with flow cytometry. The tumoricidal activity of ALP was dose and incubation time related, as, although to a lesser extent, held true for normal marrow progenitors. For some leukemias the ALP dose necessary for the elimination of 100% of the leukemic colony-forming cells is probably too toxic for normal marrow cells. The results of this study strongly support the possibility that ALP is a promising purging agent in the majority of patients with leukemias.
我们研究了烷基溶血磷脂1-十八烷基-2-甲基-sn-甘油-3-磷酸胆碱（ALP）对56例患有各种白血病患者的人白血病细胞以及正常骨髓祖细胞的影响，以评估ALP作为体外骨髓净化剂的应用。通过消除克隆性白血病细胞（白血病集落形成细胞）、抑制白血病细胞的增殖能力（[³H]胸腺嘧啶核苷掺入）以及用流式细胞术检测存活白血病细胞的消除情况来分析其杀瘤活性。ALP的杀瘤活性与剂量和孵育时间相关，正常骨髓祖细胞在一定程度上也是如此。对于某些白血病，消除100%白血病集落形成细胞所需的ALP剂量对正常骨髓细胞可能毒性过大。这项研究的结果有力地支持了ALP在大多数白血病患者中可能是一种有前景的净化剂的可能性。
